Glenmark’s Carvedilol Blood Pressure Drug Contaminated with Probable Carcinogen, Class Action Lawsuit Alleges
August 10, 2026 A class action lawsuit alleges that Glenmark's generic Carvedilol beta-blocker was tainted with carcinogenic impurities and thus unfit to sell.